There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on LifeMD (LFMD – Research Report) and Coherus Biosciences (CHRS – Research Report) with bullish sentiments.
LifeMD (LFMD)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on LifeMD, with a price target of $12.00. The company’s shares closed last Wednesday at $5.67.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on LifeMD is a Strong Buy with an average price target of $10.75, implying an 81.3% upside from current levels. In a report issued on January 8, Craig-Hallum also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Coherus Biosciences (CHRS)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Coherus Biosciences, with a price target of $13.00. The company’s shares closed last Wednesday at $2.86, close to its 52-week low of $1.43.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $11.57, a 288.3% upside from current levels. In a report issued on December 27, Citi also maintained a Buy rating on the stock with a $11.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LFMD:
- LifeMD sees 2024 revenue $195M-$205M, consensus $181.18M
- DA Davidson keeps Buy on WW after selloff on Lilly news
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD and Medifast Partner to Offer Transformative Weight Management Solution
- LifeMD, Medifast partner on weight management solution
